IP Library › Assignment 021733/0840
Patent Assignment
Reel/Frame 021733/0840

Assignment of Assignor's Interest

Recorded: 2008-10-24 Pages: 21
Assignor
CZARNIK, ANTHONY W
Executed: 2008-10-22
Assignee
PROTIA, LLC
15025 BROILI DR, RENO, NEVADA, 89511
Covered Properties (249)
Deuterium-Enriched Alendronate
Application: 12/195,504 →
Publication: US 2009/0118238
Deuterium-Enriched Amlodipine
Application: 12/195,517 →
Publication: US 2009/0062352
Deuterium-Enriched Asenapine
Application: 12/195,529 →
Publication: US 2009/0209608
Deuterium-Enriched Azithromycin
Application: 12/195,540 →
Publication: US 2009/0062220
Deuterium-Enriched Celecoxib
Application: 12/195,553 →
Publication: US 2009/0062364
Deuterium-Enriched Cetirizine
Application: 12/195,569 →
Publication: US 2009/0062305
Deuterium-Enriched Eletriptan
Application: 12/195,581 →
Publication: US 2009/0062367
Deuterium-Enriched Linezolid
Application: 12/195,589 →
Publication: US 2009/0062283
Deuterium-Enriched Sertraline
Application: 12/195,593 →
Publication: US 2009/0062399
Deuterium-Enriched Sildenafil
Application: 12/195,599 →
Publication: US 2009/0062298
Deuterium-Enriched Atorvastatin
Application: 11/745,704 →
Publication: US 2008/0280970
Deuterium-Enriched Atorvastatin
Patent: 7,745,480 →
Application: 12/098,198 →
Publication: US 2008/0280971
Deuterium-Enriched Doxazosin
Application: 12/195,807 →
Publication: US 2009/0062299
Deuterium-Enriched Ziprasidone
Application: 12/195,826 →
Publication: US 2009/0062303
Deuterium-Enriched Voriconazole
Application: 12/195,857 →
Publication: US 2009/0062310
Deuterium-Enriched Sunitinib
Application: 12/195,881 →
Publication: US 2009/0062368
Deuterium-Enriched Tiotropium
Application: 12/195,907 →
Publication: US 2009/0062325
Deuterium-Enriched Irinotecan
Application: 12/195,936 →
Publication: US 2009/0062323
Deuterium-Enriched Fluconazole
Application: 12/195,956 →
Publication: US 2009/0062357
Deuterium-Enriched Gabapentin
Application: 12/195,978 →
Publication: US 2009/0062392
Deuterium-Enriched Indiplon
Application: 12/196,003 →
Publication: US 2009/0062312
Deuterium-Enriched Tolterodine
Application: 12/196,022 →
Publication: US 2009/0062398
Deuterium-Enriched Budesonide
Application: 12/196,041 →
Publication: US 2009/0082319
Deuterium-Enriched Ciprofloxacin
Application: 12/196,053 →
Publication: US 2009/0069339
Deuterium-Enriched Lestaurtinib
Application: 11/754,390 →
Publication: US 2008/0299215
Deuterium-Enriched Oxybutynin
Patent: 7,531,685 →
Application: 11/757,333 →
Publication: US 2008/0299219
Deuterium-Enriched Sorafenib
Application: 12/196,151 →
Publication: US 2009/0069388
Deuterium-Enriched Sugammadex
Application: 12/196,166 →
Publication: US 2009/0069412
Deuterium-Enriched Aripiprazole
Application: 11/757,319 →
Publication: US 2008/0299216
Deuterium-Enriched Atrasentan
Application: 12/196,176 →
Publication: US 2009/0069402
Deuterium-Enriched Famotidine
Application: 12/196,181 →
Publication: US 2009/0069395
Deuterium-Enriched Moxifloxacin
Application: 11/758,690 →
Publication: US 2008/0306105
Deuterium-Enriched Escitalopram
Application: 11/762,818 →
Publication: US 2008/0312318
Deuterium-Enriched Fenofibrate
Application: 11/760,811 →
Publication: US 2008/0306151
Deuterium-Enriched Montelukast
Application: 11/766,140 →
Publication: US 2008/0319007
Deuterium-Enriched Olanzapine
Application: 11/765,432 →
Publication: US 2009/0005366
Deuterium-Enriched Clopidogrel
Application: 11/765,434 →
Publication: US 2008/0319004
Deuterium-Enriched Eszopiclone
Application: 11/765,435 →
Publication: US 2008/0318964
Deuterium-Enriched Ezetimibe
Application: 11/765,437 →
Publication: US 2008/0318920
Deuterium-Enriched Fluticasone Propionate
Application: 11/765,657 →
Publication: US 2008/0318915
Deuterium-Enriched Oseltamivir
Patent: 7,915,309 →
Application: 11/765,668 →
Publication: US 2008/0319064
Deuterium-Enriched Salmeterol
Application: 11/766,080 →
Publication: US 2008/0319086
Deuterium-Enriched Tenofovir
Application: 11/765,677 →
Publication: US 2008/0318904
Deuterium-Enriched Tamsulosin
Application: 11/762,810 →
Publication: US 2008/0312328
Deuterium-Enriched Pantoprazole
Application: 12/196,191 →
Publication: US 2009/0076089
Deuterium-Enriched Alfuzosin
Application: 12/196,198 →
Publication: US 2009/0076043
Deuterium-Enriched Alvimopan
Application: 12/196,205 →
Publication: US 2009/0076082
Deuterium-Enriched Ambrisentan
Application: 12/196,211 →
Publication: US 2009/0069353
Deuterium-Enriched Aroxifene
Application: 12/196,212 →
Publication: US 2009/0069380
Deuterium-Enriched Bifeprunox
Application: 11/757,322 →
Publication: US 2008/0299217
Deuterium-Enriched Valsartan
Application: 11/757,325 →
Publication: US 2008/0299218
Deuterium-Enriched Bortezomib
Application: 12/196,216 →
Publication: US 2009/0076031
Deuterium-Enriched Bosentan
Application: 12/196,225 →
Publication: US 2009/0069351
Deuterium-Enriched Bupropion
Application: 12/196,231 →
Publication: US 2009/0076161
Deuterium-Enriched Capecitabine
Patent: 7,842,675 →
Application: 12/196,236 →
Publication: US 2009/0075931
Deuterium-Enriched Ciclesonide
Application: 12/196,240 →
Publication: US 2009/0075959
Deuterium-Enriched Deferasirox
Application: 12/196,242 →
Publication: US 2009/0082412
Deuterium-Enriched Diclofenac
Application: 12/196,248 →
Publication: US 2009/0082450
Deuterium-Enriched Disufenton
Application: 12/196,251 →
Publication: US 2009/0082454
Deuterium-Enriched Dronedarone
Application: 12/196,253 →
Publication: US 2009/0076137
Deuterium-Enriched Atazanavir
Application: 12/196,255 →
Publication: US 2009/0076097
Deuterium-Enriched Atomoxetine
Application: 12/196,259 →
Publication: US 2009/0069440
Deuterium-Enriched Clazosentan
Application: 12/196,326 →
Publication: US 2009/0069352
Deuterium-Enriched Conivaptan
Application: 12/196,330 →
Publication: US 2009/0069295
Deuterium-Enriched Dasatinib
Application: 12/196,336 →
Publication: US 2009/0076025
Deuterium-Enriched Donepezil
Patent: 8,304,435 →
Application: 12/196,343 →
Publication: US 2009/0069378
Deuterium-Enriched Efavirenz
Application: 12/196,347 →
Publication: US 2009/0075991
Deuterium-Enriched Eltrombopag
Application: 12/196,359 →
Publication: US 2009/0076112
Deuterium-Enriched Enzastaurin
Application: 12/196,365 →
Publication: US 2009/0069377
Deuterium-Enriched Erlotinib
Application: 12/196,369 →
Publication: US 2009/0076042
Deuterium-Enriched Fulvestrant
Application: 12/196,380 →
Publication: US 2009/0082323
Deuterium-Enriched Gemcitabine
Application: 12/196,388 →
Publication: US 2009/0069354
Deuterium-Enriched Glimepiride
Application: 12/196,395 →
Publication: US 2009/0076125
Deuterium-Enriched Ibandronate
Application: 12/196,581 →
Publication: US 2009/0075944
Deuterium-Enriched Iclaprim
Application: 12/196,599 →
Publication: US 2009/0069357
Deuterium-Enriched Ixabepilone
Application: 12/196,627 →
Publication: US 2009/0076099
Deuterium-Enriched Lapatinib
Application: 12/196,653 →
Publication: US 2009/0215802
Deuterium-Enriched Lenalidomide
Patent: 8,288,414 →
Application: 12/196,672 →
Publication: US 2009/0069379
Deuterium-Enriched Letrozole
Application: 12/196,688 →
Publication: US 2009/0082413
Deuterium-Enriched Lisdexamfetamine
Application: 12/196,702 →
Publication: US 2009/0082465
Deuterium-Enriched Lurasidone
Application: 12/196,722 →
Publication: US 2009/0076027
Deuterium-Enriched Memantine
Application: 12/196,740 →
Publication: US 2009/0076165
Deuterium-Enriched Meropenem
Application: 12/196,773 →
Publication: US 2009/0082327
Deuterium-Enriched Methylnaltrexone
Application: 12/196,793 →
Publication: US 2009/0076051
Deuterium-Enriched Miglustat
Application: 12/196,823 →
Publication: US 2009/0069375
Deuterium-Enriched Modafinil
Application: 12/196,848 →
Publication: US 2009/0082461
Deuterium-Enriched Muraglitazar
Application: 12/196,867 →
Publication: US 2009/0076102
Deuterium-Enriched Nalmefene
Application: 12/196,879 →
Publication: US 2009/0076052
Deuterium-Enriched Naltrexone
Application: 12/196,895 →
Publication: US 2009/0082382
Deuterium-Enriched Octreotide
Application: 12/196,914 →
Publication: US 2009/0082259
Deuterium-Enriched Olopatadine
Application: 12/196,938 →
Publication: US 2009/0069413
Deuterium-Enriched Paclitaxel
Application: 12/196,958 →
Publication: US 2009/0069410
Deuterium-Enriched Pemetrexed
Application: 12/196,975 →
Publication: US 2009/0069349
Deuterium-Enriched Prasugrel
Patent: 8,669,268 →
Application: 12/196,989 →
Publication: US 2009/0069369
Deuterium-Enriched Pravastatin
Application: 12/197,015 →
Publication: US 2009/0076148
Deuterium-Enriched Quetiapine
Application: 12/197,025 →
Publication: US 2009/0082334
Deuterium-Enriched Raloxifene
Application: 12/197,038 →
Publication: US 2009/0069381
Deuterium-Enriched Risedronate
Application: 12/197,050 →
Publication: US 2009/0075940
Deuterium-Enriched Rivastigmine
Application: 12/233,638 →
Publication: US 2009/0082436
Deuterium-Enriched Anidulafungin
Application: 12/198,027 →
Publication: US 2009/0062185
Deuterium-Enriched Axitinib
Application: 12/198,034 →
Publication: US 2009/0062347
Deuterium-Enriched Hydromorphone
Application: 12/207,849 →
Publication: US 2009/0076135
Deuterium-Enriched Rosuvastatin
Application: 12/233,271 →
Publication: US 2009/0082380
Deuterium-Enriched Ruboxistaurin
Application: 12/203,331 →
Publication: US 2012/0136037
Deuterium-Enriched Tacrolimus
Application: 12/202,275 →
Publication: US 2009/0069366
Deuterium-Enriched Prazosin
Application: 12/198,042 →
Publication: US 2009/0062300
Deuterium-Enriched Pregabalin
Application: 12/198,045 →
Publication: US 2009/0062393
Deuterium-Enriched Tegaserod
Application: 12/233,641 →
Publication: US 2009/0082419
Deuterium-Enriched Tesaglitazar
Application: 12/233,285 →
Publication: US 2009/0082441
Deuterium-Enriched Tiagabine
Application: 12/233,301 →
Publication: US 2009/0082401
Deuterium-Enriched Tipranavir
Application: 12/198,050 →
Publication: US 2009/0062346
Deuterium-Enriched Varenicline
Application: 12/198,054 →
Publication: US 2009/0062257
Deuterium-Enriched Vernakalant
Application: 12/202,276 →
Publication: US 2009/0069404
Deuterium-Enriched Vildagliptin
Application: 12/233,322 →
Publication: US 2009/0082420
Deuterium-Enriched Vinflunine
Application: 12/206,212 →
Publication: US 2009/0076055
Deuterium-Enriched Viramidine
Application: 12/233,645 →
Publication: US 2009/0082414
Deuterium-Enriched Zoledronic Acid
Application: 12/233,330 →
Publication: US 2009/0082312
Deuterium-Enriched Maraviroc
Application: 12/198,058 →
Publication: US 2009/0062331
Deuterium-Enriched Fesoterodine
Application: 12/198,064 →
Publication: US 2009/0062385
Deuterium-Enriched Lasofoxifene
Application: 12/198,069 →
Publication: US 2009/0062374
Deuterium-Enriched Latanoprost
Application: 12/198,074 →
Publication: US 2009/0062561
Deuterium-Enriched Pf-184298
Application: 12/198,082 →
Publication: US 2009/0062373
Deuterium-Enriched Dalbavancin
Application: 12/198,088 →
Publication: US 2009/0062182
Deuterium-Enriched Pelitrexol
Application: 12/198,090 →
Publication: US 2009/0062316
Deuterium-Enriched Milnacipran
Application: 12/203,348 →
Publication: US 2009/0069431
Deuterium-Enriched Sdx-101
Patent: 7,956,080 →
Application: 12/233,344 →
Publication: US 2009/0082417
Deuterium-Enriched Apixaban
Application: 12/206,223 →
Publication: US 2009/0076069
Deuterium-Enriched Armodafinil
Application: 12/233,354 →
Publication: US 2009/0082462
Deuterium-Enriched Aztreonam
Application: 12/203,363 →
Publication: US 2009/0069286
Deuterium-Enriched Entecavir
Application: 12/206,281 →
Publication: US 2009/0076038
Deuterium-Enriched Frovatriptan
Application: 12/203,369 →
Publication: US 2009/0069399
Deuterium-Enriched Nebivolol
Application: 12/203,386 →
Publication: US 2009/0069415
Deuterium-Enriched Olmesartan
Application: 12/203,472 →
Publication: US 2009/0069397
Deuterium-Enriched Rufinamide
Application: 12/203,487 →
Publication: US 2009/0069390
Deuterium-Enriched Saxagliptin
Application: 12/205,590 →
Publication: US 2009/0076118
Deuterium-Enriched Amoxicilin
Application: 12/205,607 →
Publication: US 2009/0075965
Deuterium-Enriched Bicalutamide
Application: 12/205,627 →
Publication: US 2009/0076158
Deuterium-Enriched Fosamprenavir
Application: 12/205,637 →
Publication: US 2009/0075942
Deuterium-Enriched Lamotrigine
Application: 12/205,653 →
Publication: US 2009/0076010
Deuterium-Enriched Nelarabine
Patent: 7,846,912 →
Application: 12/205,664 →
Publication: US 2009/0075930
Deuterium-Enriched Odansetron
Patent: 7,919,516 →
Application: 12/205,677 →
Publication: US 2009/0076107
Deuterium-Enriched Odiparcil
Application: 12/205,691 →
Publication: US 2009/0075914
Deuterium-Enriched Radafaxine
Application: 12/206,295 →
Publication: US 2009/0075994
Deuterium-Enriched Retapamulin
Application: 12/205,701 →
Publication: US 2009/0076071
Deuterium-Enriched Clarithromycin
Application: 12/202,278 →
Publication: US 2009/0069255
Deuterium-Enriched Telavancin
Application: 12/202,277 →
Publication: US 2009/0069219
Deuterium-Enriched Aliskiren
Application: 12/196,576 →
Publication: US 2009/0082458
Deuterium-Enriched Alogliptin
Application: 12/196,597 →
Publication: US 2009/0082376
Deuterium-Enriched Amibegron
Application: 12/196,623 →
Publication: US 2009/0076145
Deuterium-Enriched Aprepitant
Application: 12/196,654 →
Publication: US 2009/0076007
Deuterium-Enriched Arformoterol
Application: 12/196,677 →
Publication: US 2009/0306215
Deuterium-Enriched Bazedoxifene
Application: 12/196,692 →
Publication: US 2009/0076144
Deuterium-Enriched Bendamustine
Application: 12/196,711 →
Publication: US 2009/0082416
Deuterium-Enriched Bms-690514
Application: 12/196,734 →
Publication: US 2009/0076034
Deuterium-Enriched Bromfenac
Application: 12/196,751 →
Publication: US 2009/0076150
Deuterium-Enriched Ceftriaxone
Application: 12/196,762 →
Publication: US 2009/0075967
Deuterium-Enriched Dapoxetine
Application: 12/196,788 →
Publication: US 2009/0076163
Deuterium-Enriched Darunavir
Application: 12/196,828 →
Publication: US 2009/0076138
Deuterium-Enriched Decitabine
Application: 12/196,853 →
Publication: US 2009/0075920
Deuterium-Enriched Desvenlafaxine
Application: 12/196,866 →
Publication: US 2009/0076162
Deuterium-Enriched Caspofungin
Application: 12/196,886 →
Publication: US 2009/0075870
Deuterium-Enriched Dianicline
Application: 12/196,898 →
Publication: US 2009/0076059
Deuterium-Enriched Doripenem
Application: 12/196,920 →
Publication: US 2009/0075969
Deuterium-Enriched Dutasteride
Application: 12/196,942 →
Publication: US 2009/0076057
Deuterium-Enriched Ed-71
Application: 12/196,952 →
Publication: US 2009/0075953
Deuterium-Enriched Enalapril
Application: 12/210,280 →
Publication: US 2009/0076126
Deuterium-Enriched Fingolimod
Application: 12/196,977 →
Publication: US 2009/0082471
Deuterium-Enriched Fluvastatin
Application: 12/196,991 →
Publication: US 2009/0082418
Deuterium-Enriched Fondaparinux
Application: 12/197,007 →
Publication: US 2009/0075910
Deuterium-Enriched Fospropofol
Application: 12/197,022 →
Publication: US 2009/0075947
Deuterium-Enriched GSK625433
Application: 12/197,042 →
Publication: US 2009/0076100
Deuterium-Enriched Guanfacine
Application: 12/197,055 →
Publication: US 2009/0082459
Deuterium-Enriched Itraconazole
Application: 12/207,861 →
Publication: US 2009/0076028
Deuterium-Enriched Levetiracetam
Application: 12/233,651 →
Publication: US 2009/0082422
Deuterium-Enriched Methylphenidate
Application: 12/207,879 →
Publication: US 2009/0076079
Deuterium-Enriched Mycophenolate Mofetil
Application: 12/207,894 →
Publication: US 2009/0076000
Deuterium-Enriched Nicorandil
Application: 12/208,621 →
Publication: US 2009/0076095
Deuterium-Enriched Nicraven
Application: 12/208,639 →
Publication: US 2009/0076085
Deuterium-Enriched Paliperidone
Application: 12/208,653 →
Publication: US 2009/0076035
Deuterium-Enriched Palosetron
Application: 12/208,859 →
Publication: US 2009/0227623
Deuterium-Enriched Ranolazine
Application: 12/208,667 →
Publication: US 2009/0076018
Deuterium-Enriched Risperidone
Patent: 7,776,866 →
Application: 12/208,684 →
Publication: US 2009/0076036
Deuterium-Enriched Rivaroxaban
Application: 12/208,703 →
Publication: US 2009/0076264
Deuterium-Enriched Ropinirole
Application: 12/206,307 →
Publication: US 2009/0076124
Deuterium-Enriched Rosiglitazone
Application: 12/206,316 →
Publication: US 2009/0076093
Deuterium-Enriched Saredutant
Application: 12/210,314 →
Publication: US 2009/0076083
Deuterium-Enriched Senicapoc
Application: 12/208,716 →
Publication: US 2009/0076157
Deuterium-Enriched Tafenoquine
Application: 12/206,330 →
Publication: US 2009/0076072
Deuterium-Enriched Tapentadol
Application: 12/208,731 →
Publication: US 2009/0076164
Deuterium-Enriched Telaprevir
Application: 12/233,655 →
Publication: US 2009/0082366
Deuterium-Enriched Topiramate
Application: 12/208,743 →
Publication: US 2009/0076128
Deuterium-Enriched Topotecan
Patent: 8,026,249 →
Application: 12/206,368 →
Publication: US 2009/0076056
Deuterium-Enriched Trabectedin
Application: 12/208,756 →
Publication: US 2009/0076017
Deuterium-Enriched Tramiprosate
Application: 12/208,872 →
Publication: US 2009/0076167
Deuterium-Enriched Valacyclovir
Application: 12/206,396 →
Publication: US 2009/0076039
Deuterium-Enriched Valganciclovir
Application: 12/208,773 →
Publication: US 2009/0076040
Deuterium-Enriched Zanamivir
Application: 12/206,405 →
Publication: US 2009/0076133
Deuterium-Enriched Buprenorphine
Application: 12/233,657 →
Publication: US 2009/0082383
Deuterium-Enriched Carvediolo
Application: 12/205,712 →
Publication: US 2009/0076116
Deuterium-Enriched Desloratidine
Application: 12/233,665 →
Publication: US 2009/0082385
Deuterium-Enriched Eplivanserin
Application: 12/210,321 →
Publication: US 2009/0076159
Deuterium-Enriched Etoricoxib
Application: 12/208,888 →
Publication: US 2009/0076087
Deuterium-Enriched Fexofenadine
Application: 12/210,326 →
Publication: US 2009/0076080
Deuterium-Enriched Finasteride
Application: 12/208,901 →
Publication: US 2009/0076058
Deuterium-Enriched Fosaprepitant
Application: 12/208,919 →
Publication: US 2009/0076008
Deuterium-Enriched Imatinib
Application: 12/233,677 →
Publication: US 2009/0082361
Deuterium-Enriched Lapaquistat
Application: 12/233,690 →
Publication: US 2009/0088416
Deuterium-Enriched Laropiprant
Application: 12/208,936 →
Publication: US 2009/0076117
Deuterium-Enriched Larotaxel
Application: 12/210,330 →
Publication: US 2009/0076127
Deuterium-Enriched Levalbuterol
Application: 12/233,695 →
Publication: US 2009/0082468
Deuterium-Enriched Levocedtirizine
Application: 12/233,702 →
Publication: US 2009/0082364
Deuterium-Enriched Losartan
Application: 12/208,959 →
Publication: US 2009/0076104
Deuterium-Enriched Lubiprostone
Application: 12/233,712 →
Publication: US 2009/0082442
Deuterium-Enriched Lumiracoxib
Application: 12/233,719 →
Publication: US 2009/0082452
Deuterium-Enriched Mk-0812
Application: 12/208,970 →
Publication: US 2009/0076065
Deuterium-Enriched MK0974
Application: 12/208,981 →
Publication: US 2009/0075977
Deuterium-Enriched Mometasone
Application: 12/233,725 →
Publication: US 2009/0082318
Deuterium-Enriched Nvp-BEZ234
Application: 12/233,734 →
Publication: US 2009/0082387
Deuterium-Enriched Oxalplatin
Application: 12/210,339 →
Publication: US 2009/0076139
Deuterium-Enriched Oxcarbazepine
Application: 12/233,743 →
Publication: US 2009/0082335
Deuterium-Enriched Pioglitazone
Patent: 8,722,710 →
Application: 12/233,751 →
Publication: US 2009/0082405
Deuterium-Enriched Posaconazole
Application: 12/234,229 →
Publication: US 2009/0082363
Deuterium-Enriched Ramelteon
Application: 12/234,290 →
Publication: US 2009/0082432
Deuterium-Enriched Ramipril
Application: 12/210,385 →
Publication: US 2009/0076119
Deuterium-Enriched Satavaptan
Application: 12/210,391 →
Publication: US 2009/0075997
Deuterium-Enriched Simvastatin
Application: 12/209,005 →
Publication: US 2009/0076134
Deuterium-Enriched Sitagliptin
Application: 12/209,020 →
Publication: US 2009/0076013
Deuterium-Enriched Sumatriptan
Application: 12/206,417 →
Publication: US 2009/0076121
Deuterium-Enriched Tazobactam
Application: 12/209,031 →
Publication: US 2009/0075966
Deuterium-Enriched Telbivudine
Application: 12/234,317 →
Publication: US 2009/0082306
Deuterium-Enriched Telithromycin
Application: 12/210,405 →
Publication: US 2009/0075917
Deuterium-Enriched Temsirolimus
Application: 12/209,043 →
Publication: US 2009/0076060
Apparatus for and Method of Servicing Conveyor Belt Return Rollers During Belt Operation
Patent: 7,971,705 →
Application: 12/234,324 →
Publication: US 2010/0072037
Deuterium-Enriched Tigecycline
Application: 12/210,290 →
Publication: US 2009/0076153
Deuterium-Enriched Tirapazamine
Application: 12/210,413 →
Publication: US 2009/0076011
Deuterium-Enriched Vorinostat
Application: 12/210,298 →
Publication: US 2009/0076154
Deuterium-Enriched Xaliproden
Application: 12/210,431 →
Publication: US 2009/0076048
Deuterium-Enriched Zolpidem
Application: 12/210,438 →
Publication: US 2009/0076066
Deuterium-Enriched Escitalopram
Deuterium-Enriched Montelukast
Deuterium-Enriched Olanzapine
Deuterium-Enriched Clopidogrel
Deuterium-Enriched Eszopiclone
Deuterium-Enriched Ezetimibe
Deuterium-Enriched Fluticasone Propionate
Deuterium-Enriched Oseltamivir
Deuterium-Enriched Salmeterol
Deuterium-Enriched Tenofovir
Deuterium-Enriched Tamsulosin
Related Assignments (2)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jul 18, 2011
From: PROTIA, LLC
To: DEUTERIA PHARMACEUTICALS INCE
Reel/Frame 026609/0689 →
Assignment of Assignor's Interest Jan 31, 2013
From: DEUTERIA PHARMACEUTICALS INC
To: PROTIA, LLC
Reel/Frame 029732/0858 →